PT Itama Ranoraya Tbk.

irra

-5.14%

Overview

IRRA Overview

PT Itama Ranoraya Tbk is an Indonesia-based healthcare company, which is engaged in offering healthcare solutions. The Company operates in the field of wholesale trading of laboratory equipment, pharmaceutical equipment, and medical devices for humans. The Company carries out its operations through four products, namely the non-electromedical sterile medical devices, in-vitro diagnostic, electromedical sterile medical devices, and other products. Its business segment focuses on in-vitro diagnostic (IVD), medical imaging, surgical instrument and disposable, critical care, blood banking and transfusion, cardiovascular, brain management, cancer, urology, and maternal and neonatal care. Its products include Oneject, Abbott, Terumo, Becton Dickinson (BD), HMD, Vestfrost, Balmed, iGene, AVIMAC, and HemoCue.

51015ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: IRRA

Development
Market Cap.
IDR 750.89Billion

~$46.97M USD

Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Supplies & Distributions
Sector
Healthcare

Valuation

IRRA Valuation Metrics

498

IDR
-5.1%

Closing Price on 2024-05-22

Price to Equity

144.45

P/E

At 144.45x P/E TTM, IRRA.JK is trading at a premium to its peers in the Healthcare Equipment & Providers sector (avg 16.1x).

Price to Book

1.64

P/B

At 1.64x P/B TTM, IRRA.JK is trading in line with its peers in the Healthcare Equipment & Providers sector.

Price to Sales

1.08

P/S

At 1.08x P/S TTM, IRRA.JK is trading at a discount to its peers in the Healthcare Equipment & Providers sector.

Valuing PT Itama Ranoraya Tbk. based on its trailing twelve months (TTM) valuation metrics against its peers in the Healthcare Equipment & Providers sector

Historical Price to Earnings

Other Valuation Metrics

Valuing PT Itama Ranoraya Tbk. relative to other stocks in the Healthcare Equipment & Providers sector

Price/Cash Flow
-19.68x
Price/Forward Earnings
-
Enterprise Value/Revenue
1.29x
Enterprise Value/EBITDA
28.77x
PEG Ratio
-0.46x

Analyst Ratings

No analyst ratings available yet.

Last closing: IDR4982024-05-22
IDR 304.57

Considerably Lower Intrinsic Value: Analyst's intrinsic value is of IRRA is IDR305, which is 38% lower than IRRA's last closing price of IDR498 (as of 2024-05-22).

Valuation Recap of IRRA stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 144.45x is above the ID market average of 8.70x and is trading at a premium to peers in the Healthcare Equipment & Providers sector (16.15x). In fact, less than 25% of its peers trade at a higher P/E ratio than IRRA.

High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 1.64x is similar to the peers average of 1.64x in the Healthcare Equipment & Providers sector.

Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 1.08x is below the peers average of 2.81x in the Healthcare Equipment & Providers sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of IRRA's valuation relative to its current sales and future earnings growth.

Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. IRRA's P/CF ratio of -19.68x is considered healthy by analysts.

Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. IRRA's EV/R ratio of 1.29x is considered extremely underpriced by the market The average EV/R ratio for the Healthcare Equipment & Providers sector is 2.87x.

Medium
Considerably Lower Intrinsic Value: Analyst's intrinsic value is of IRRA is IDR 304.57, which is 38% lower than IRRA's last closing price of IDR 498.00.

Peers

IRRA Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk72.16T27.06T 30.45T 2.77T 26.083.37
MIKAPT Mitra Keluarga Karyasehat Tbk.42.97T7.34T 4.26T 0.92T 46.917.38
SILOPT Siloam International Hospitals Tbk.32.72T10.98T 11.19T 1.21T 27.014.13
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk21.45T3.89T 3.57T 0.95T 22.566.34
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.61T 2.50T -0.04T -534.7211.09
HEALPT Medikaloka Hermina Tbk.19.88T8.80T 5.78T 0.44T 45.455.14
PRAYPT Famon Awal Bros Sedaya Tbk9.35T4.70T 1.84T 0.22T 43.113.34
TSPCTempo Scan Pacific Tbk9.16T11.32T 13.12T 1.18T 7.781.19
SOHOPT Soho Global Health Tbk6.32T4.75T 8.20T 0.37T 17.022.63
OMEDPT Jayamas Medica Industri Tbk5.47T2.58T 1.74T 0.26T 21.072.46
Competitiveness Recap of IRRA stock
WeightNotesScore
High
At a market cap of IDR 750.89 billion, IRRA.JK ranks 10 in Market Cap out of 10 companies in the Healthcare sector.

High
At a PE of 144.45, IRRA.JK ranks 1 out of 10 companies in the Healthcare sector for P/E value. The average PE is -15.44 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. false

Medium
At a PE of 144.45, IRRA.JK is trading at a higher PE than that of its subsector peers in Healthcare Equipment & Providers (median of 16.15). false

Medium
At a revenue of IDR 0.70 trillion, IRRA.JK ranks 10 in Revenue out of 10 companies in the Healthcare sector.

Medium
At a profit of IDR 0.01 trillion, IRRA.JK ranks 9 in Profit out of 10 companies in the Healthcare sector.

Future

Future Growth of IRRA

Growth Forecasts

No data available

Sector Benchmark

Healthcare Equipment & Providers companies in Indonesia are growing at a projected rate of 24.79% against the IDX average of +13.8%.

Healthcare Equipment & Providers sector overview
No data is available for IRRA at the moment.
Future growth prospect of IRRA
WeightNotesScore
High
IRRA's projected growth rate of 24.79% is above the ID market average of 13.80%.

High
The Healthcare Equipment & Providers sub-sector is projected to grow revenue by 24.01% in 2025. This number is higher than the previous year 2024's growth rate of 10.78%. This bodes well for IRRA's revenue growth prospects in the next 2 years.

Medium
The Healthcare Equipment & Providers sub-sector is projected to increase earnings by 18.17% in 2025. This number is higher than the previous year 2024's EPS growth of -1.27%. This bodes well for IRRA's earnings growth prospects in the next 2 years.

Medium
IRRA and its peers in the Healthcare Equipment & Providers sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2025. Specifically, earnings are projected to increase by 22.78% in 2025 while revenue growth is projected to increase by 20.04%. These macroeconomic trends will likely be a tailwind for IRRA's earnings growth prospects in the next 2 years.

Loading...
Loading...

Management

Executive Management

President Director

Heru Firdausi Syarif15.2 years
Dodi Nurzani
Director
Nanan Menanta Lasahido
Director
Hendry Herman
Director
NamePositionShares%
Dr. Tjandra Yoga AditamaPresident Commissioner203,600< 0.01
Expressed in millions IDR, unless otherwise stated

Ownership

IRRA Ownership

Others
16.26%
Insiders
83.74%
Institutions
0%
NameNumber of SharesOwnership (%)Value
Pt Global Dinamika Kencana1,254,583,80078.41624.78B
Public253,030,00015.82126.01B
Pt Itama Ranoraya Tbk92,182,6005.7645.91B
Dr. Tjandra Yoga Aditama203,6000.010.10B
No data is available for IRRA at the moment.